We are targeting HER2+ve breast cancers and also prostate cancers. The research involves several Stanford scientists with expertise in prodrug therapies, bioimaging, oncology, breast cancer surgery, prostate cancer, blood-brain barrier characterization, biostatistics, a local industry, and (at SRI) pharmacologists, who will participate in eventual clinical trials. The research is part of a nationwide NIH NCATS consortium. We are using exosomes to deliver therapy specifically to breast tumors and metastasis to the brain. Exosomes/microvesilces, the body's "natural antigen delivery system" are vesicles secreted by most cells in the body. They have an abundant surface protein (Lamp2b) that can be conjugated to ligands such as those that specifically target overexpressed HER2 marker (breast cancer) and PSMA (prostate cancer); C1C2 domains of lactadherin can also be used for this purpose. Our industrial collaborators have developed XPack and XStamp technologies that permit, respectively, insertion of proteins of interest into the exosomes, and display of desired targeting ligands on exosome surface. We have used chemical, Ab (ScFv; larger antibodies), and aptamer ligands and have already achieved a degree of specific targeting; these are now being improving. More recently we have thoroughly investigated the nature of exosomes and other extracellular vesicles and their differential capacity to deliver biomolecules (see the PNAS early edition article, accessible via the Publication link).
The ongoing work involves bioinformatics to identify epitopes vital for the action of these proteins and discover small molecule inhibitors of these segments, so as increase the efficacy of these staple antibiotics; and investigation of the effect of antibiotics with and without the inhibitors on metabolic networks.
An extension of this work is collaborative research with NASA AMES Research Center at Moffett Field, Mountain View, CA. We and others have shown that bacteria become more virulent and human immune response less competent under microgravity of space. Based on our previous work, we have hypothesized that the new mechanism we have identified in bacterial antibiotic resistance will have even a more important role in increasing bacterial antibiotic resistance in space flights. This is being tested using a nanosatellite and state-of-the art hardware for conducting experiments in space and beaming the results to Earth via telemetry. The experiment is expected to fly coming August.
